BioGend Therapeutics Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 38.47 million compared to TWD 5.91 million a year ago. Net loss was TWD 30.02 million compared to TWD 34.47 million a year ago. Basic loss per share from continuing operations was TWD 0.26 compared to TWD 0.33 a year ago. Diluted loss per share from continuing operations was TWD 0.26 compared to TWD 0.33 a year ago.
For the six months, sales was TWD 49.28 million compared to TWD 10.88 million a year ago. Net loss was TWD 81.25 million compared to TWD 79.1 million a year ago. Basic loss per share from continuing operations was TWD 0.69 compared to TWD 0.77 a year ago. Diluted loss per share from continuing operations was TWD 0.69 compared to TWD 0.77 a year ago.